---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-047560"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2024-04-24T23:59:59+00:00"
generated_at: "2026-06-03T09:48:32.203535+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Acrivon reports 50% confirmed ORR with ACR-368 in OncoSignature-positive gynecological cancers; cash ~$234M

## Summary
- Phase 2b: 50% confirmed ORR in OncoSignature-positive ovarian/endometrial (10 pts), 0% ORR in negative (16), p=0.0038.
- Median duration of response not yet reached; all responders remain on treatment.
- ACR-2316 dual WEE1/PKMYT1 inhibitor IND filing accelerated to Q3 2024; clinical trial expected Q4 2024.
- Preliminary cash $110M at March 31; pro forma $234M after private placement, funding into H2 2026.
- Initial prospective validation of AP3 platform ability to predict ACR-368 responders.

## SEC filing metadata
- accession: 0000950170-24-047560
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2024-04-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000095017024047560/0000950170-24-047560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000095017024047560/acrv-20240424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-047560
- JSON: https://secwatch.observer/filing/0000950170-24-047560.json
- Plain text: https://secwatch.observer/filing/0000950170-24-047560.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.